Alloy Therapeutics Secures $40M Series E Funding at $1B Valuation to Advance AI-Driven Drug Discovery Platform

April 15, Boston – Alloy Therapeutics, a biotechnology ecosystem company driving the future of drug discovery and development through an AI-powered platform and integrated services, announced the completion of a $40 million Series E financing round, marking a significant step in the company’s evolution from an antibody discovery pioneer to a comprehensive biotechnology infrastructure provider. This latest funding values Alloy at $1 billion.

Since its establishment in 2017, Alloy Therapeutics has collaborated with more than 200 partners on a variety of biopharmaceutical modalities, including antibodies, bispecific antibodies, genetic medicines, and cell therapies, resulting in over 100 licensed therapeutic programs. Among these, 22 have advanced to clinical development, including two that are already in Phase 3 clinical trials. Building on its drug discovery foundation, Alloy has expanded its capabilities across the entire drug development lifecycle, encompassing pharmacology, preclinical and clinical development services, as well as biologics manufacturing.

Errik Anderson, founder and CEO of Alloy Therapeutics, said:"Alloy is building the infrastructure layer that connects discovery, development, and data across the global biopharmaceutical industry. We are bridging the significant strengths of traditional biopharma and cutting-edge TechBio to reimagine what’s possible in drug creation. Technological innovation, including artificial intelligence at every step of the process, is driving rapid advancements that no single pharmaceutical company can keep up with. Alloy's collaborative, service-oriented model allows our partners to stay ahead without having to innovate in every aspect or intermittently hire the personnel and infrastructure they might need."

Alloy Therapeutics will use the proceeds to accelerate growth in three priority areas:Deepening its core discovery services in antibodies, gene therapies, and cell therapies; expanding its downstream preclinical and clinical development services; and accelerating its AI/ML capabilities and the data layer that connects everything. The future of drug development belongs to capital-efficient builders: virtual biotech and lean development teams that require world-class infrastructure without the need to own it. Alloy is such a platform: connecting proprietary AI, real-world data, and wet lab execution on-demand, while federating and safeguarding partner data at every step.

Series E round major investors include 8VC, JIC VGI, ECHO CAPITAL, and multiple family offices, joining Alloy Therapeutics' existing investors Mubadala Capital, Presight Ventures, Thiel Capital, Founders Fund, Alexandria Venture Investments, Gaingels Spark LLC, and Ulysses Diversified Holdings.

Alex Kolicich from 8VC stated:"Over the past decade, we have witnessed Errik systematically build Alloy into a company that is quietly redefining large-scale drug development. While all industries are being disrupted by artificial intelligence before our eyes, Alloy understands that the true disruption in biopharmaceuticals comes from integrating AI as part of an 'x-in-the-loop' strategy with real-world capabilities."

The company continues to expand its footprint through centers of excellence in the United States, Japan, the Middle East, and emerging innovative markets, establishing a distributed, locally executed model for the next era of decentralized drug development.

Hanae Suzuki, Head of Life Science Investments at JIC VGI, stated:"Strengthening Japan's position in the global life sciences field requires investment in infrastructure that enables innovation to develop faster, more efficiently, and without borders. Alloy’s model — connecting world-class proprietary technologies and services across regions, including its growing operations in Japan — not only enhances Japan’s ability to integrate into the global innovation ecosystem but also supports the development of globally competitive talent, which is precisely the global ecosystem we aim to support."

Follow the official account below to see the world!